Actively Recruiting
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)
Led by University Hospital, Montpellier · Updated on 2025-07-10
70
Participants Needed
1
Research Sites
237 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough. There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points. The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient. FRENCH-MRD-CRC is the French study of the european GUIDE.MRD project.
CONDITIONS
Official Title
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Colon or rectal cancer, clinical tumor stage I-III
- Patient 18 years or older
- Scheduled for curative intent resection surgery (including "compromised" curative resections)
- Participation in FRENCH.MRD.CRC part 1 - SURGERY
- Colorectal cancer, UICC stage III
- Has received curative-intent resection and is a candidate for adjuvant chemotherapy (3- or 6-months regime)
You will not qualify if you...
- Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome
- Verified distant metastases
- Malignant colorectal polyps diagnosed after polypectomy
- Patients who are unlikely to comply with the protocol or unable to return for subsequent visits
- Pregnant or nursing woman, or in childbearing age and not willing to use contraception
- Protected and vulnerable adult
- Not covered by Health insurance
- Patient unable to understand and sign written informed consent
- Inflammatory bowel disease (Crohn's disease or ulcerative colitis) related colon cancer
- Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included)
- Treated with neoadjuvant chemo-radiation therapy
- Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)
- Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Montpellier
Montpellier, Hérault, France, 34295
Actively Recruiting
Research Team
C
Catherine ALIX-PANABIERES, PhD
CONTACT
T
Thomas BARDOL, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here